Global Phenylketonuria (PKU) Pipeline Report 2016 – Research and Markets

This report provides comprehensive information on the therapeutic development for Phenylketonuria (PKU), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Phenylketonuria (PKU) and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Phenylketonuria (PKU) Overview
  3. Therapeutics Development
  4. Pipeline Products for Phenylketonuria (PKU) – Overview
  5. Pipeline Products for Phenylketonuria (PKU) – Comparative Analysis
  6. Phenylketonuria (PKU) – Therapeutics under Development by Companies
  7. Phenylketonuria (PKU) – Therapeutics under Investigation by Universities/Institutes
  8. Phenylketonuria (PKU) Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Phenylketonuria (PKU) – Products under Development by Companies
  13. Phenylketonuria (PKU) – Products under Investigation by Universities/Institutes
  14. Phenylketonuria (PKU) – Companies Involved in Therapeutics Development
  • BioMarin Pharmaceutical Inc.
  • Codexis, Inc.
  • Erytech Pharma SA
  • SOM Innovation Biotech SL
  • Synthetic Biologics, Inc.

Leave a Reply

Your email address will not be published. Required fields are marked *